CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aprogen Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aprogen Biologics Inc
304, Haetae Greenpia Villat
38, Wiryeseong-Daero, Songpa-Gu
Phone: +82 25614011p:+82 25614011 SEOUL, 05641  South Korea Ticker: 003060003060
Business Summary
Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5999 Miscellaneous retail stores, not elsewhere classified
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Jae SeopKim 60 10/13/2023 4/25/2008
Co-Chief Executive Officer, Director Jeong ChulKim 67 10/13/2023 9/23/2013
Managing Director Jong SuKang 57
6 additional Officers and Directors records available in full report.

Business Names
Business Name
003060
Aprogen, Inc.
CHUNGGEI PHARM.CO.,LTD
Korea Schnell Pharma Co., Ltd.
Schnell Biopharmaceuticals

General Information
Number of Employees: 96 (As of 12/31/2015)
Outstanding Shares: 65,753,081 (As of 4/16/2024)
Shareholders: 52,017
Stock Exchange: KRX
Fax Number: +82 25614012


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024